Pembro plus chemo followed by resection and adjuvant pembro improves on SOC for early NSCLC

Neoadjuvant Pembrolizumab for Lung Cancer | NEJMПодробнее

Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squamous NSCLCПодробнее

KEYNOTE-407: pembrolizumab plus chemo improves OS and PFS in NSCLCПодробнее

Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breas...Подробнее

KEYNOTE-091 and IMPOWER010: adjuvant chemotherapy for NSCLCПодробнее

Advances in Immunotherapy & Resectable Non-Small Cell Lung CancerПодробнее

KEYNOTE-522: Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs place...Подробнее

S1 Episode 4: Managing Lung Cancer With Neoadjuvant and Adjuvant TherapyПодробнее

2020 Evolution | Lung Cancer Case PresentationПодробнее

Lung Cancer ASCO 2023 Highlights - OncBrothers (Rohit and Rahul Gosain) with Dr. Charu AggarwalПодробнее

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...Подробнее

Ramucirumab plus pembrolizumab improves OS in advanced NSCLCПодробнее

Current Status of Adjuvant Therapy for NSCLCПодробнее

KEYNOTE-407: 3-year follow-up of pembrolizumab plus chemo in NSCLCПодробнее

INTerpath-002: pembrolizumab with a neoantigen therapy in completely resected NSCLCПодробнее

IMpower010 supports adjuvant atezolizumab in early-stage NSCLC | Heather WakeleeПодробнее

Perioperative therapies in NSCLCПодробнее

Advanced NSCLC: Refining Clinical Pathways in the Rapidly Evolving Therapeutic LandscapeПодробнее

First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year fol...Подробнее

Pembrolizumab with Chemotherapy in Early-Stage NSCLC: Dr. Priya Eshpuniyani on Phase 3 Trial | CRSFПодробнее

KEYNOTE-042: revolutionizing lung cancer treatment with pembrolizumab monotherapyПодробнее